Biogen News

A vaccine for smoking! Power hungry Eli Lilly execs! Flu shots from caterpillars! It all happened in November 2009.

Unsubstantiated whisperings about Biogen Idec and its controversial multiple sclerosis drug took an ugly turn to the truth on Thursday when European regulators disclosedA another new case of progressive multifocal leukoencephalopathy , a serious brain infection known as PML, in a relapsed MS patient receiving Tysabri infusions.

As mentioned in my last BNET Pharma posting , Biogen Idec 's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML - with most confirmed cases centered in Europe, in particular Germany.

Shares of Biogen Idec fell Friday after European regulators said that they have initiated a safety review of the multiple sclerosis drug Tysabri, which Biogen makes in Research Triangle Park.

Biogen Idec Inc. and Biovitrum said Monday they will move a potential hemophilia B treatment into a late-stage study.

Biotech drugmaker Biogen Idec said Friday it has extended its tender offer for shares of Facet Biotech Corp., after the company's board unanimously rejected the hostile takeover bid.

Biotech shoppers made some big bets as the summer drew to a close, capped off by Biogen Idec's bid to acquire all of the outstanding shares of Facet Biotech for $14.50 per share in cash, a 64 percent premium to its closing price the previous day.

Biogen Idec Inc. today announced that it has submitted a proposal to the Board of Directors of Facet Biotech Corporation to acquire all of the outstanding shares of Facet for $14.50 per share in cash.

With Biogen Idec Inc. making its $14.50 per share, or $347 million, bid for Facet Biotech Corp.

Biogen Idec announced today that it made an unsolicited offer to acquire Facet Biotech for $14.50 a share in cash.

Biotech's Dog Days Ah, the dog days of summer...those long, glorious days that make it impossible to get the kids to sleep before 10 PM.

The withdrawal of a new multiple-sclerosis drug has brought scrutiny to millions of dollars in insider stock sales at Biogen Idec and executive bonuses awarded before the company disclosed a death and illness that led to pulling the drug from the market.

The debacle over faulty drugs besetting the pharmaceutical industry has spread to the biotech sector, with one of its best-performing companies and a partner pulling their highly touted multiple-sclerosis drug from the market after one patient died and another fell seriously ill.

Bret Holley - Oppenheimer & Co. Jim Birchenough - Barclays Capital Michael Aberman - Credit Suisse Kareem De Felipe - Citigroup Geoffrey Porges - Sanford Bernstein Geoff Meecham - J.P. Morgan Eun Yang - Jefferies Jason Zhang - BMO Capital Maged Shenouda - UBS Josh Schimmer - Leerink Swann Presentation Operator Good morning my name is Celeste and I ...

The two entered into an exclusive license and collaboration deal over the drug Fampridine-SR. The experimental pill may help patients with multiple sclerosis improve their ability to walk.

Biogen Idec Inc. said yesterday an arbitration panel affirmed its right to participate in strategic decisions in a partnership with Genentech , which includes the cancer drug Rituxan and other drug candidates.

Carl C. Icahn , the corporate raider turned activist investor, claimed a major victory in his long-running battle with Biogen Idec on Wednesday, announcing that two allies had been placed on the board of the biotechnology company.

Still, the biotech firm said results for the election of a second rebel were too close to call.

NEW YORK, June 3 /PRNewswire/ -- Carl Icahn announced today that Biogen is acting in its usual shareholder unfriendly way by manipulating the annual meeting of shareholders in order the prevent the votes that have been submitted from being counted.